SR One
SR One is the corporate venture capital arm of GlaxoSmithKline.
Business Model:
Revenue: $11.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed SR One Information
Geographic Data
Address: 1 Broadway
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$500M
Social
Linkedin
Crunchbase
Metrics
3,468,928Website Global Rank
4,128Website Monthly Traffic
Twitter Followers
Description
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
Contact Phone:
+16105671000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 10/2019 | Arcellx | Series B | 0 |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 10/2012 | Principia Biopharma | Series A | 12.5M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 1/2009 | Melinta Therapeutics | Series D | 0 |
| 11/2012 | Applied Genetics Technologies Corporation | Series B | 0 |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 9/2020 | Palleon Pharmaceuticals | Series B | 100M |
| 6/2018 | Decibel Therapeutics | Series C | 55M |
| 6/2004 | Nucleonics | Series B | 49.2M |
| 9/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2013 | F-Star Therapeutics | Series A | 0 |
| 1/2017 | Translate Bio | Series C | 51M |
| 2/2002 | Avantium | Venture Round | 0 |
| 10/2001 | Therion Biologics | Venture Round | 0 |
| 9/2021 | ADARx Pharmaceuticals | Series B | 75M |
| 9/2003 | Therion Biologics | Venture Round | 0 |
| 5/2000 | Xenogen Corporation | Series E | 30.6M |
| 10/2006 | Morphotek | Series D | 0 |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 12/2012 | River Vision Development | Series A | 17M |
| 6/2015 | Gladius Pharmaceuticals | Series A | 3.3M |
| 3/2015 | Thrasos | Series D | 21M |
| 10/2012 | Thrasos | Series C | 35M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 1/2014 | ZappRx | Seed Round | 1M |
| 10/2020 | Dren Bio | Series A | 0 |
| 5/2009 | Bird Rock Bio | Series A | 13M |
| 6/2018 | Nimbus Therapeutics | Series B | 65M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 12/2010 | Semprus BioSciences | Series B | 18M |
| 9/2005 | Algeta | Series A | 28.9M |
| 10/2014 | Atopix Therapeutics | Series A | 0 |
| 10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
| 12/2005 | Hypnion | Series B | 0 |
| 9/2018 | Morphic Therapeutic | Series B | 0 |
| 12/2015 | Navitor Pharmaceuticals | Series B | 33M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 4/2015 | CRISPR Therapeutics | Series A | 35M |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 7/2011 | HTG Molecular Diagnostics | Series D | 0 |
| 5/2010 | Ntprx | Series B | 43M |
| 8/2021 | ARS Pharmaceuticals | Series D | 55M |
| 11/2010 | iPierian | Series B | 29M |
| 7/2016 | Progyny | Series B | 14.7M |
| 5/2017 | Progyny | Series B | 10M |
| 9/2013 | iPierian | Venture Round | 30M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 1/2023 | ADARx Pharmaceuticals | Series B | 0 |
| 11/2022 | Rezo | Series A | 0 |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 7/2008 | NuPathe | Series B | 30M |
| 12/2022 | Pulmocide | Series C | 0 |
| 1/2021 | River 3 Renal | Series A | 40M |
| 4/2010 | Bicycle Therapeutics | Seed Round | - |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 3/2015 | Nimbus Therapeutics | Series B | 43M |
| 11/2006 | PharmaKodex | Series A | 13.5M |
| 8/1998 | MicroMass Communications | Venture Round | 7M |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 8/2006 | Ablynx | Series C | 50M |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 6/2009 | Anaphore | Series A | 13M |
| 6/2022 | Dren Bio | Series B | 0 |
| 6/2016 | Morphic Therapeutic | Series A | 0 |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 3/2003 | Hypnion | Series B | 47.5M |
| 4/2017 | ZappRx | Series B | 25M |
| 10/2010 | Dicerna Pharmaceuticals | Series B | 4M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 1/2015 | Nkarta Therapeutics | Series A | 11M |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 6/2014 | True North Therapeutics | Series A | 22M |
| 7/2012 | Akamis Bio | Series B | 34.1M |
| 2/2009 | Genocea Biosciences | Series A | 23M |
| 7/2007 | CalciMedica | Series A | 1.5M |
| 11/2020 | F-Star Therapeutics | Post-IPO Equity | 0 |
| 10/2016 | Bicycle Therapeutics | Series A | - |
| 10/2015 | Puridify | Series A | 3.4M |
| 3/2003 | Alere | Venture Round | 5.1M |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 12/2014 | Avhana Health | Seed Round | 0 |
| 11/1999 | Physician Verification Services | Venture Round | - |
| 4/2016 | Second Genome | Series B | 51M |
| 2/2002 | Nucleonics | Series A | 1.6M |
| 12/2009 | CalciMedica | Series C | 12M |
| 6/2010 | Constellation Pharmaceuticals | Series B | 22.3M |
| 6/2011 | Constellation Pharmaceuticals | Series B | 15M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 1/2005 | Predix Pharmaceuticals | Series C | 0 |
| 10/2015 | Decibel Therapeutics | Series A | 52M |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 6/2011 | Nimbus Therapeutics | Series A | 24M |
| 1/2002 | Gryphon Therapeutics | Series B | 26M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 1/2005 | OctoPlus | Series B | 23.9M |
| 1/2021 | River 2 Renal | Series A | 40M |
| 3/2005 | Novalar Pharmaceuticals | Series C | 27M |
| 10/2019 | MiroBio | Series A | 33.2M |
| 6/2022 | Ancora Biotech LLC | Series A | 60M |
| 11/2000 | Onyvax | Venture Round | 14.9M |
| 2/2016 | Spero Therapeutics | Series B | 30M |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2017 | Pulmocide | Series B | 30.4M |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 8/2015 | Principia Biopharma | Series B | 15.3M |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 11/2020 | Decibel Therapeutics | Series D | 82.2M |
| 7/2014 | Atox Bio | Series E | 23M |
| 4/2014 | Principia Biopharma | Series B | 50M |
| 5/1999 | Xenogen Corporation | Series D | 11M |
| 6/2015 | Spero Therapeutics | Series A | 0 |
| 1/2012 | Translate Bio | Series A | 20.7M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 11/2010 | Syntaxin | Series C | 29M |
| 5/2014 | Puridify | Seed Round | 1.4M |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 5/2015 | Akamis Bio | Series C | 38.8M |
| 4/2014 | Spero Therapeutics | Series A | 0 |
| 12/2013 | VHSquared | Series A | - |
| 6/2022 | MiroBio | Series B | 0 |
| 5/2021 | Pulmocide | Series C | 0 |
| 1/2018 | Pandion Therapeutics | Series A | 58M |
| 11/2007 | Novalar Pharmaceuticals | Series D | 30M |
| 6/2006 | Melinta Therapeutics | Series C | 0 |
| 12/1997 | Onyvax | Venture Round | - |
| 5/2006 | Onyvax | Series C | 14.9M |
| 1/2002 | Melinta Therapeutics | Series A | 22M |
| 9/2022 | Nimbus Therapeutics | Venture Round | 0 |
| 8/2016 | Tioma Therapeutics | Series A | 86M |
| 11/2003 | Protein Forest | Series A | 19M |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 1/2009 | CalciMedica | Series C | 4M |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 12/2017 | Atox Bio | Series F | 0 |
| 12/2021 | Nomic Bio | Series A | 17M |
| 5/2018 | Propeller Health | Series D | 20M |
| 2/2007 | Locus Pharmaceuticals | Series E | 30.2M |
| 1/1999 | Message Pharmaceuticals | Venture Round | 6.3M |
| 8/2005 | Protez Pharmaceuticals | Series B | 15M |
| 7/2015 | Translate Bio | Series B | 0 |
| 12/2003 | Linguagen | Series A | 2M |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 3/2020 | Design Therapeutics | Series A | 45.5M |
| 4/2015 | ZappRx | Series A | 14M |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 4/2011 | F-Star Therapeutics | Venture Round | 0 |
| 10/2016 | Propeller Health | Series C | 21.5M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 1/2008 | POINT Biomedical | Private Equity Round | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 6/2022 | MiroBio | Series B | 0 |
| 6/2022 | Ancora Biotech LLC | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 12/2021 | nplex biosciences | Series A | 0 |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 9/2021 | ADARx Pharmaceuticals | Series B | 0 |
| 8/2021 | ARS Pharmaceuticals | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
